来自MSN1 个月
New treatment target for neuroendocrine prostate cancer discovered
Chandra's lab, discovered that HSP60-dependent aggressive neuroendocrine prostate cancer characteristics are associated with upregulation of β-catenin signaling. β-catenin is a multifunction ...
UroToday5 年
ASCO GU 2019: Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic ...
San Francisco, CA (UroToday.com)Recent studies have identified genomic alterations in metastatic castrate resistant prostate cancer (mCRPC), but our understanding of the ... Comparing enzalutamide ...